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The currently used antivirals in the treatment of inﬂuenza in Japan include amantadine, oseltamivir, zanamivir, laninamivir, and
peramivir. We compared the eﬃcacy of intravenous peramivir with that of other neuraminidase inhibitors for treating pediatric
inﬂuenza. The present study included 223 inﬂuenza patients (≤18 years) who presented at the Hikita Pediatric Clinic between
February and April 2011. We compared fever duration after starting treatment with antiviral drugs. Because inhalation drugs are
diﬃcult to use in <5-year-old patients and because of the potential adverse eﬀects of oseltamivir in teenagers, we created two
diﬀerent age groups (<10-year-old group and 5–18-year-old group) to evaluate treatment results. In inﬂuenza A patients between
5 and 18 years old, the median fever duration after treatment with zanamivir was 2 days, compared with 1 day for peramivir
(P = 0.0242). In inﬂuenza B patients between 5 and 18 years old, the median fever duration after treatment with laninamivir was
3 days, compared with 1 day for peramivir (P = 0.0097). We found no signiﬁcant diﬀerence for any of the other combinations of
drug/disease type/age groups. No adverse eﬀects were observed with the antiviral drugs used. The results suggest that peramivir is
very useful in pediatric inﬂuenza patients.
1.Introduction
Ofthevariousrespiratorydiseases,inﬂuenzaisamajorcause
of mortality and morbidity among patients, particularly the
v e r yy o u n ga n dt h ee l d e r l y[ 1, 2]. Two options are available
for moderating the eﬀect of the inﬂuenza virus: vaccines,
which although eﬀective, are underutilized and not com-
pletely protective because of frequent antigenic shifts in the
viral surface proteins and antiviral drugs [2, 3]. Antiviral
drugs have emerged as attractive options in the battle against
inﬂuenza. Amantadine, oseltamivir, zanamivir, laninamivir,
and peramivir are the ﬁve antiviral drugs currently used to
treat inﬂuenza in Japan [2]. However, ﬁrm guidelines for
prescribing these drugs remain to be established.
Amantadine is limited in eﬀectiveness because of its lack
of activity against inﬂuenza B virus [4] and the rapid emer-
gence of resistant viral strains. Hemagglutinin and neuram-
inidase, two glycoproteins present on the viral surface, have
antiviraltargets[5].Recently,oseltamivir andzanamivir, two
inﬂuenza neuraminidase inhibitors, have commonly been
prescribed for inﬂuenza A and B [6–12]. Laninamivir is a
long-acting neuraminidase inhibitor for the treatment of
inﬂuenza. A single inhalation of laninamivir is eﬀective for
the treatment of inﬂuenza, including that caused by the osel-
tamivir-resistant viruses, in adults [13, 14]. However, seri-
ously ill and pediatric patients need a parenteral formulation
because the injectable drug is much easier to administer in
such cases than oral oseltamivir, inhaled zanamivir, or lan-
inamivir.
In Japan, peramivir has recently been approved for use
not only in adults but also in children over 1 month of age
[15]. In this study, we compared the eﬃcacy of intravenous
peramivir with that of other neuraminidase inhibitors for
treating inﬂuenza infections in pediatric patients.
2.MaterialandMethods
The present study included 223 patients under the age of 18
years diagnosed with inﬂuenza at the Hikita Pediatric Clinic
between February and April 2011. The patients presented2 International Journal of Pediatrics
Table 1: Comparison of the eﬀectiveness of oseltamivir, zanamivir, laninamivir, and peramivir against inﬂuenza virus infection.
Groups
Therapy Number
of patients
Median age in
months (range)
Duration of fever
before treatment,
median day (range)
Duration of fever
after treatment,
median day (range)
P value
Inﬂuenza type Ages (years)
Inﬂuenza A 0–9
Oseltamivir 83 51 (3–118) 1 (0–2) 2 (0–6) 0.4499
Peramivir 22 41.5 (2–106) 1 (0–2) 1.5 (1–3)
Inﬂuenza B 0–9
Oseltamivir 41 81 (25–118) 1 (0–2) 2 (0–4) 0.6435
Peramivir 13 75 (10–118) 0 (0–2) 2 (1–4)
Inﬂuenza A 5–18
Laninamivir 1 80 (80-80) 0 (0-0) 1 (1-1) Not
performed
Peramivir 15 94 (72–219) 1 (0–2) 1 (1-2)
Zanamivir 18 34.5 (69–198) 1 (0–2) 2 (0–3) 0.0242∗
Inﬂuenza B 5–18
Laninamivir 13 134 (91–164) 0 (0–2) 3 (1–5) 0.0097∗
Peramivir 13 98 (63–167) 1 (0-1) 1 (1–4)
Zanamivir 20 120 (87–179) 0 (0–2) 2 (0–4) 0.2979
“Not performed” indicates that statistical analysis was not performed because the number of subjects was too small.
∗indicates a signiﬁcant diﬀerence between peramivir and the other administered drug.
(Both the 0–9 years group and the 5–18 years group included 5–9-year-old children treated with peramivir).
with a complaint of fever lasting for less than 48h, and
they were clinically diagnosed with rapid diagnostic tests.
Specimensfromnasalswabsornasalaspiratesweresubjected
to antigen detection. Commercial antigen detection kits
basedonimmunochromatography(TheQuickChaserFluA,
B rapid antigen test [Mizuho Medy Co., Ltd. Saga, Japan])
was used for the diagnosis of inﬂuenza A or B. Subsequently,
after obtaining informed consent from the parents, 35
patients diagnosed with inﬂuenza A by the rapid antigen A,
B test underwent a 2009 inﬂuenza A H1N1 virus infection
test using the Quick Chaser Flu AH1pdm (Mizuho Medy) to
diﬀerentiate patients with 2009 H1N1 inﬂuenza from those
with seasonal inﬂuenza.
The eﬃcacy, potential adverse eﬀects, and convenience
of administration of the ﬁve antiviral drugs were explained
to the patients and/or their families prior to study initiation.
The choice of antivirals for inﬂuenza treatment was then dis-
cussed, and after obtaining informed consent from patients
and/or their families, all patients underwent antiviral ther-
apy. Laninamivir was administered as a single-inhalation
dose of 40mg for patients aged ≥10 years or 20mg for pa-
tients aged <10 years. Peramivir was administered intrave-
nously as a single dose of 10mg/kg/dose (maximum 300mg/
dose) over a period of 15min. Oral oseltamivir was pre-
scribed twice per day in divided dosages for 5 days (4mg/
kg/day, maximum of 150mg/day). Zanamivir was admin-
istered twice per day at an inhalation dosage of 20mg/day
for 5 days.
In 2007, the Ministry of Health, Labor, and Welfare, Ja-
pan, issued emergency instructions suspending the use of
oseltamivir in patients aged 10–19 years [16]. Accordingly,
oseltamivir was not prescribed for the teenage patients with
inﬂuenzainourstudy.Inaddition,inhaleddrugsarediﬃcult
to use in infants. Therefore, laninamivir and zanamivir were
prescribed for patients aged ≥5y e a r s .W ec r e a t e d2a g e
groups for statistical analysis: patients aged <10 years and
those aged between 5 and 18 years. We compared the dura-
tion of fever after initiating antiviral therapy. Fever was
considered positive if the patient’s body temperature was
≥37.5◦C. When a patient’s body temperature dropped and
remained at <37.5◦C for 48 continuous h, the fever was
considered as resolved.
Data were analyzed using JMP software version 8.0.2
(SAS Institute, Cary, NC, USA). The Wilcoxon rank-sum
test and/or the Kruskal-Wallis rank-sum test were used to
compare the ages of inﬂuenza patients treated with laninam-
ivir, oseltamivir, peramivir, or zanamivir. We used Kaplan-
Meier analysis and the log-rank test to compare the duration
of fever after antiviral therapy initiation. A P value of <0.05
was considered statistically signiﬁcant.
3. Results
We treated 131 (70 males) and 92 (53 males) patients with
inﬂuenza A and B, respectively. Nine of 35 (25.7%) patients
tested positive in the 2009 inﬂuenza A H1N1 test. Patients
were administered the following antiviral drugs: laninamivir
(n = 14), oseltamivir (n = 125), peramivir (n = 45),
and zanamivir (n = 39). No patient was treated with aman-
tadine in this study. The median ages of the patients treated
with laninamivir, oseltamivir, peramivir, and zanamivir were
132.5 months (range, 80–164), 56.5 months (range, 3–135),
76 months (range, 2–219), and 124.5 months (range, 59–
198), respectively. No adverse eﬀects were observed with any
of the antiviral drugs used in this study.
We compared <10-year-old inﬂuenza patients who were
administered either oseltamivir or peramivir (Table 1). The
age of patients treated with oseltamivir was not signiﬁcantly
diﬀerentfromthatofpatientstreatedwithperamivir.Wealso
compared 5–18-year-old inﬂuenza patients treated with per-
amivir, zanamivir, or laninamivir. The age of patients did not
signiﬁcantly diﬀer between treatment groups. The medianInternational Journal of Pediatrics 3
duration of fever after zanamivir treatment in 5–18-year-old
patients with inﬂuenza A was 2 days (range, 0–3 days),
whereas that after peramivir treatment was 1 day (range, 1-
2 days); this diﬀerence was statistically signiﬁcant (P =
0.0283). The median duration of fever after laninamivir
treatment in 5–18-year-old patients with inﬂuenza B was 3
days (range, 1–5 days), whereas that after peramivir treat-
ment was 1 day (range, 1–4 days); this diﬀerence was also
statistically signiﬁcant (P = 0.0097). No other signiﬁcant
diﬀerences were observed for any of the other drug/disease
type/age group combinations.
4. Discussion
Hernandez et al. reported their clinical experience with chil-
dren (n = 11) hospitalized for 2009 inﬂuenza A (H1N1) and
treated with peramivir [17]. In their study, all patients had
rapidly progressing, radiographically conﬁrmed viral pneu-
monia with respiratory failure. In our study, peramivir was
administered to patients with inﬂuenza, including 2009 in-
ﬂuenza A (H1N1), seasonal inﬂuenza H3N2, and inﬂuenza
B. None of the patients had severe disease and all were treat-
ed as outpatients. Severe adult inﬂuenza infection has been
reportedly treated with peramivir [18]. Although oseltamivir
and zanamivir are used for severe inﬂuenza infections such
as encephalopathy [19] ,p e r a m i v i ri sm o r es u i t a b l ef o rs u c h
infections because it is much easier to administer (intra-
venously) to a severe case when compared with oral osel-
tamivir or inhaled zanamivir. Currently, most patients in Ja-
pan with an inﬂuenza-like illness are tested using rapid diag-
nostic tests and treated with an appropriate choice of anti-
viraldrugsifr esultspr o v epositi v e[20].Particularly,afterthe
2009 H1N1 inﬂuenza pandemic virus was isolated, antiviral
therapy was recommended for all pediatric inﬂuenza pa-
tients.
A limitation of this study was the small study sample and
the lack of a randomized open label study; therefore, more
data are needed before the clinical implications of this study
become clear. We compared only fever duration and did not
analyze any other symptoms because inﬂuenza patients in
Japan can only return to school 48 hours after fever reso-
lution. However, we were able to conﬁrm the usefulness of
peramivir in children. Randomized case-control studies with
suﬃciently large populations will be conducted during the
next inﬂuenza season following approval by an ethics com-
mittee.
Recent developments in antigen detection tests have
made it possible to diﬀerentiate between inﬂuenza A, 2009
inﬂuenza A (H1N1), and inﬂuenza B. Therefore, on deter-
mination of the variant involved, physicians, patients, and
their families can make informed decisions regarding choice
of antiviral drug. The inhalation drugs laninamivir and za-
namivir are diﬃcult to use in infants. Vaccines are not com-
pletely protective because of frequent antigenic shifts in the
viral surface proteins, as observed in the last pandemic.
The results of this study suggest that peramivir is an im-
portant and a feasible therapeutic option for pediatric in-
ﬂuenza patients.
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